News Release

Mallinckrodt Pharmaceuticals to Hold Investor Briefing in New York

DUBLIN--(BUSINESS WIRE)--Nov. 8, 2013-- Mallinckrodt (NYSE:MNK), a global specialty pharmaceutical and global medical imaging company, will hold an investor briefing on November 14, 2013. The meeting will be held at the Grand Hyatt at 109 East 42nd Street at Grand Central Terminal New York, NY from 8:30am to 9am Eastern Standard Time. Mark Trudeau, President and CEO of Mallinckrodt, along with members of Mallinckrodt’s senior management team, will present.

Individuals who are unable to attend the meeting in person will be able to view a live video and webcast at Mallinckrodt’s website: or participate by telephone: 877-348-9353 in the U.S – and 253-237-1159 outside the U.S. The access code for all callers is 93659517. A replay of the presentation and the presentation materials will be available at the same website following the conclusion of the meeting.


Mallinckrodt is a global specialty pharmaceuticals business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company’s Specialty Pharmaceuticals segment includes branded and generic drugs, and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt has approximately 5,500 employees worldwide with direct sales in roughly 70 countries. To learn more about Mallinckrodt, visit

Source: Mallinckrodt

John Moten, 314-654-6650
Vice President, Investor Relations
Lynn Phillips, 314-654-3263
Manager, Media Relations
Meredith Fischer, 314-654-3318
Senior Vice President, Communications